Nanjing Tongnuo Kang Pharmaceutical Technology Co., Ltd. develops small molecule antitumor drugs targeting malignant tumors and autoimmune diseases by integrating artificial intelligence with multi-omics technology throughout the drug discovery and development process. The company focuses on unmet clinical needs and undruggable targets, employing indirect targeting strategies such as synthetic lethality and RNA small molecules to create novel therapeutics with global intellectual property.
Funding
Funding not disclosed
Founders
Product
Problem
Malignant tumors and autoimmune diseases present significant unmet clinical needs due to the challenges in drugging certain biological targets. Traditional drug discovery methods often struggle to address these undruggable targets, hindering the development of effective therapies.
Solution
Nanjing Tongnuo Kang Pharmaceutical Technology Co., Ltd. is developing small molecule antitumor drugs by integrating artificial intelligence (AI) and multi-omics technologies throughout the drug discovery and development process. The company focuses on unmet clinical needs and undruggable targets in malignant tumors and autoimmune diseases, employing indirect targeting strategies such as synthetic lethality and RNA small molecules to create novel therapeutics. This approach provides new avenues for developing molecules against difficult-to-drug targets. The company aims to develop original small molecule new drugs with global intellectual property.
Target Audience
The primary target audience includes patients with malignant tumors and autoimmune diseases, as well as pharmaceutical companies seeking innovative drug candidates for these conditions.
Features
- AI-driven drug discovery platform integrating multi-omics data for target identification and validation
- Focus on indirect targeting strategies, including synthetic lethality and RNA small molecules
- Development of small molecule drugs for malignant tumors and autoimmune diseases
- Pipeline of "globally new" research programs targeting unmet clinical needs